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CHAPTER I
REVIEW OF LITERATURE
Intraocular Pressure
The canine eye is composed of three major parts; the globe, the optic
nerve, and the accessory structures. The globe or eyebal'l's outer coat or tunic
is fibrous to give the eye a rigid shape. It has a transparent anterior cornea and
an opaque posterior sclera. The middle vascular tunic or uvea is composed of
the pigmented iris, the ciliary body, and the choroid. The inner tunic is the light
sensitive nerve layer termed the retina.
The anterior chamber is between the posterior surface of the cornea and
the anterior surface of the iris. The posterior chamber lies between the
posterior iris and the anterior lens surface (Figure 1).
The aqueous humor is the transparent fluid that fills the anterior and
posterior chambers. The aqueous humor supplies nutrition to and removes
waste products from the avascular cornea and lens. Aqueous is formed by the
epithelium of the ciliary body. The mechanisms involved are diffusion,
ultrafiltration, and active secretion (Gum 1991).
The vitreous humor fills the vitreous cavity which is the space posterior
to the lens. The vitreous provides the support for the lens and also supports
the retina against the choroid (Coulter, 1984).
The ciliary body is a highly vascular structure with a large surface area.
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Figure 1. The Eye
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(Renwick, 1994). As the aqueous exits the ciliary body, it enters the posterior
chamber then the anterior chamber via the pupil. Due to the temperature
difference between the cornea and the warm iris, aqueous humor circulates in
an upward flow in the anterior chamber, ie convection.
The aqueous humor exits the globe via the trabecular meshwork at the
iridocorneal angle, the area between the cornea and iris. It is then resorbed
through the scleral venous plexus into the peripheral circulation. This is termed
the conventional aqueous outflow pathway (Van Buskirk, 1979) and accounts
for approximately eighty-five percent of the outflow.
The other fifteen percent of outflow has been described as an
unconventional outflow pathway (Barrie, 1985). This unconventional or
uveoscleral pathway involves diffusion through the iris, ciliary body, and
sclerociliary cleft to eventually be resorbed by the choroidal and scleral
circulation.
The amount of fluid within the globe is measured as the rigidity of the
globe and is expressed as the intraocular pressure. The rate of aqueous
formation should equal the rate of drainage. Intraocular pressure is measured
by a variety of methods and expressed in millimeters of mercury, (mmHg). The
intraocular pressure of the adult, healthy canine species is between 15-25
mmHg (Coulter, 1984). Normal intraocular pressure can also vary with age of
the animal, restraint, positioning, breed, body condition, and many other factors
(Renwick, 1993).
The aqueous outflow channels and trabecular meshwork are innervated
by the sympathetic nervous system and provide a nervous influence on
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intraocular pressure (Gwin, 1979).
An increase in intraocular pressure is due to an obstruction to outflow
facility and not to hypersecretion of aqueous by the ciliary epithelium (Quinn,
1977) and an increase in intraocular pressure beyond the limits of health of the
eye is the definition of glaucoma (Quinn, 1977).
Measurement of Intraocular Pressure
There are three methods of measuring intraocular pressure in the
domestic animal. 1.Digital palpation is a crude estimation of intraocular
pressure. 2.lndentation tonometry using a Schiotz tonometer ~ (Schiotz®,
Interstate) is a relatively easy procedure but the validity depends upon the
patient, the clinician, and the instrument. 3.Applanation tonometry measures
intraocular pressure by measuring the force required to flatten a constant area
of the cornea (Gelatt, 1991 b). The Mackay-Marg Model 12 applanation
tonometer (Biotronics) provides an accurate estimation of intraocular pressure
(lOP) in man and most domestic animals (Gelatt, 1991 b).
With indentation and applanation tonometry, a topical anesthetic solution,
proparacaine (Proparacaine®, Bausch and Lomb), is applied to the globe prior to
tonometry. Proparacaine's main site of action is the nerve cell membrane
where it interferes with the increase in membrane permeability to sodium ions
and limits permeability through the lipid layer (Weisbecker, 1994). It does not
influence lOP. Tonometry with the Mackay-Marg Model 12 applanation
tonometer is then performed.
Drugs Used in Treatment of Glaucoma
Medical therapy for glaucoma involves either decreasing the inflow of
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aqueous humor or increasing its outflow.
There are four primary classes of drugs used in the medical treatment of
canine glaucoma (Lewis, 1989; Brightman, 1980; Gelatt, 1979). These include:
(a) miotics, (b) adrenergic agents, (c) hyperosmotic diuretics, and (d) carbonic
anhydrase inhibitors.
Miotics include parasympathomimetics such as pilocarpine, carbachol,
demecarium, and echothiophate. These agents produce pupillary constriction,
ciliary muscle contraction, and increase aqueous outflow through the trabecular
meshwork (Gelatt, 1991 a). Miotics also produce a vasodilation of blood vessels
to enhance drainage of aqueous.
The adrenergic agents reduce lOP by increasing aqueous outflow by
stimulating the alpha adrenergic receptors and blocking the beta adrenergic
receptors to decrease aqueous production. Examples include epinephrine,
depivalyl epinephrine (DPE), and timolol maleate. The decrease in lOP produced
by adrenergic agents alone has not been sufficient to maintain glaucoma
control. The side effect of contact blepharitits has also limited the use of
epinephrine and DPE (Lewis, 1980).
The hyperosmotic diuretic agents such as mannitol and glycerin, are used
for short term rapid reduction of lOP. These are primarily used prior to surgery
to reduce intraocular volume.
Carbonic anyhdrase inhibitors limit carbonic anhydrase in the ciliary
epithelium thus decreasing aqueous formation and lowering lOP (Lewis, 1980).
The agents used in the canine patient include dichlorphenamide, acetazolamide,
ethoxzolamide, and methazolamide. These are commonly used in combination
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with the miotics.
Pharmacology of Alpha-2 Adrenergic Receptor Agonists
Xylazine hydrochloride (Rompun®, Haver) chemically is 2(2,6-
dimethylphenylamino)-4H-5,6-dihydro-1 ,3-thiazine hydrochloride (Figure 2) with
the code name Bay Va 1470 (Booth, 1982). Pharmacologically, it is classified
as a sedative, a muscle relaxant, and an analgesic (Clark, 1969). However, it
is not an anesthetic or tranquilizer. The Food and Drug Administration, FDA,
has approved xylazine usage in the cat, dog, deer, elk, and horse in 20/0 and
10% solutions (Booth, 1982; Lumb, 1984).
Studies in cats and rabbits suggest that xylazine stimulates central alpha
adrenoceptors that are distinct from peripheral alpha adrenoceptors (Loc, 1974).
It is a potent antinociceptive agent (Schmitt, 1974) that is antagonized by the
selective alpha-2 antagonist yohimbine (Yobine®, Lloyd Laboratories) (Hedler,
1981 ). Since yohimbine has been identified as a specific blocking agent at the
presynaptic receptor region then xylazine's major target must also be the
presynaptic alpha-2 region (Booth, 1982).
Muscle relaxation is mediated by the inhibition of intraneural transmission
of central nervous system impulses (Lumb, 1984). Studies have shown that
the effects of xylazine are not due to cholinergic, dopaminergic, histaminergic,
or serotonergic pathways (Hsu, 1981; Schmitt, 1974).
Other documented effects of xylazine administration include: bradycardia
(Haskins, 1986), a transient second-degree atrioventricular block (Kerr et al
1972), emesis-most commonly in the cat (Lumb, 1984), arterial hypotension
due to the depressant effect on cardiac contractility and decreased cardiac
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output (Gross et ai, 1992; Antonaccio, 1973) and ventricular arrhythmias
including fibrillations induced due to sensitization to epinephrine (Lumb, 1984).
A dose dependent hypothermia and an environmentally temperature
dependent hyperthermia have been observed in cats (Lumb 1984). In rats and
primates, when used in combination with ketamine (Ketaset®, Bristol), xylazine
produces hypothermia.
Acute abdominal distension may occur in large dogs due to aerophagia
or parasympatholytic activity (Booth, 1982). In the horse, when the head
characteristically drops, there is decreased muscle tone with penile prolapse
often occurring, as well as an increase in urination (England, 1992).
The ocular effects of xylazine have been described in the cat, rabbit,
monkey, horse, and goat (Burke, 1986; Seleium, 1990; Kumar, 1976; Hsu,
1981 ). Effects ranged from prolonged palpebral and corneal reflexes (Kumar,
1976), to decreased intraocular pressure (Seleim, 1990; Burke, 1986; Trim,
1985; McClure 1976), unilateral miosis (Burke, 1986), and a dose-dependent
mydriasis (Hsu, 1981). The ocular effects have not been described in the
canine patient.
Detomidine hydrochloride (Dormosedan, Orion Corporation, Farmos)
(Figure 3) chemically is 1 H imidazole, 4-[(2,3-dimethylphenyl)methyl]-
hydrochloride. Pharmacologically, it is a non-narcotic sedative and analgesic
with a dose dependent depth and duration (England, 1992). It has been
approved by the FDA for use in mature and yearling horses in a 1% solution
(England, 1992).
Clinically, with detomidine administration, heart rate is dramatically
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decreased with blood pressure elevated early then gradually returning to normal
(England, 1992). Partial atrioventricular and sinoauricular blocks have been
noted due to a change in cardiac muscle conductivity (Farmos).
Ocular effects have been studied in cats, rabbits, and isolated bovine
ciliary process (Jin et at, 1991). Topically administered detomidine produced
a dose dependent decrease in lOP in both cats and rabbits in both the treated
and untreated eye (Jin et ai, 1991). In the bovine ciliary process, the
stimulated cyclic adenylate cyclase activity was decreased (Jin et ai, 1991).
These studies suggest that detomidine also stimulates alpha-2
adrenoceptors because it is antagonized by selective alpha-2 adrenoceptor
antagonists (England, 1992).
Xylazine hydrochloride and detomidine hydrochloride are both marketed
as selective alpha-2 adrenergic receptor agonists. These agents exert their
influence on the prejunctional alpha-2 adrenoceptors (Figure 4)(Burke, 1986) by
a negative feedback system to regulate transmitter, ie norepinephrine, release
during stimulation; thereby, attenuating response to lower levels of nerve
stimulation (Burke, 1986). Norepinephrine is inhibited from stimulation of the
alpha-1 receptors and subsequent production of aqueous humor (Hoffman,
1980; Starke, 1981; Berthelsen, 1977) (Figure 4).
Yohimbine (Figure 5) is an indole alkaloid found in nature. Chemically,
it is a 17a-hydroxyyohimban-16a-carboxylic acid methyl ester (Goldberg, 1983;
Gross et ai, 1992; Hsu, 1983). It is a selective alpha-2 antagonist and prevents
the autoinhibitory release of norepinephrine from the presynaptic nerve
terminals by the alpha-2 agonists (Hsu, 1983).
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Currently, there are no studies available on simultaneous measurements
of lOP and blood pressure with topically administered xylazine or detomidine in
the dog to characterize the role of the alpha-2 adrenoceptor; therefore, it is the
purpose of this study to provide this information.
Nitric Oxide-Regulation of Intraocular Pressure
Nitric oxide is a gaseous, tissue soluble intercellular, signaling molecule
and an extracellular paracrine factor to carry information between cells
(Nathanson, 1993; Sparrow, 1994). Nitric oxide (NO) is synthesized from the
amino acid L-arginine by a group of enzymes, the nitric oxide synthases (NOS)
via the L-arginine nitric oxide pathway (Moncada et ai, 1989). NOS converts
the guanidino nitrogen of L-arginine to L-citrulline, with the formation of
equimolar amounts of NO (Marietta et ai, 1988; Palmer et ai, 1988; Bush et ai,
1992).
Nitric oxide (NO) has recently been evaluated as a vasodilator and to play
a role in lOP (Nathanson, 1993; Mandai et ai, 1994). NOS exists as several
isozymes, the two categories of NOS are constitutive (eNOS) and inducible
(iNOS)(Fosterman et ai, 1991). Cells that contain eNOS quickly and transiently
produce small amounts of NO in response to agonists which raise intracellular
Ca2 + concentrations, while cells with iNOS produce large amounts of NO for a
prolonged period following a lag of several hours during which the enzyme is
induced (Fosterman et ai, 1991). The iNOS is the form that increases in uveitis
(Mandai et ai, 1994) and which influences a decrease in lOP. iNOS is found in
neutrophils, endothelial cells, vascular smooth muscle, and retinal pigment
epithelium. The nitric oxide produced in endothelial cells relaxes blood vessels
11
by regulation of vascular tone and stimulates cytosolic guanylate cyclase
(Nathanson, 1993)(Figure 6). By increasing blood flow and vascular
permeability, the lOP is reduced with the increased aqueous outflow
(Nathanson,1993; Mandai et ai, 1994). Nitric oxide has a variety of other
effects including mediation of macrophage cytotoxic effects (Sparrow, 1994).
Nitric oxide has been studied in the retina of chick embryos (Zeevalk, 1994) and
in Lewis rats with endotoxin-induced uveitis (Mandai et ai, 1994) and may also
promote the breakdown of the blood aqueous barrier (Mandai et ai, 1994). NG-
nitro-L-arginine methyl ester hydrochloride (NNA)(Figure 7) is a competitive NOS
inhibitor and decreases nitric oxide production via NOS (Mandai, 1994; Zeevalk,
1994).
Derivatives of L-arginine, such as NG-methyl-arginine and N-nitro-L-
arginine have been demonstrated to inhibit nitric oxide synthase in various
biological tissues both in vivo and in vitro (Lechevalier et ai, 1994; Mandai et
ai, 1994; Zeevalk, 1994). These compounds are commonly used as tools to
investigate the role of endogenous nitric oxide in regulating various
physiological and pathological conditions (Moncada et ai, 1991; Moncada and
Higg, 1993).
Nitric oxide synthase inhibitors have been shown to block the release of
nitric oxide and increase mean arterial blood pressure in a dose dependent
manner (Lechevalier et ai, 1994) and depress the infiltration of
polymorphonuclear cells in the anterior uvea in endotoxin ... induced uveitis
(Mandai et ai, 1994).
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Specific Objectives of the Proposed Research Project
There are at present no reports dealing with the effects of alpha-2
adrenergic receptor agonists such as xylazine and detomidine and NOS inhibitor
on canine lOP and SABP. Therefore, the specfic objectives of this study are:
1: to characterize the effects of alpha-2 adrenergic agents such as xylazine and
detomidine on lOP and SABP, 2: to characterize the effects of NG-nitro-L-
arginine methyl ester, an NOS inhibitor, on lOP and SABP, and 3: to
characterize the interactions between xylazine and the NG-nitro-L-arginine
methyl ester on lOP and SABP in conscious dogs.
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CHAPTER II
THE EFFECTS OF XYLAZINE, DETOMIDINE, AND NG-NITRO-L-ARGININE
METHYL ESTER ON THE CANINE INTRAOCULAR PRESSURE
Abstract
The effects of unilateral application of alpha-2 adrenergic receptor
agonists such as xylazine and detomidine and NG-nitro-L-arginine methyl ester
to the left eye on intraocular pressure (lOP) and systemic arterial blood pressure
(SABP) were determined in conscio·us dogs. Xylazine at 0.1, 0.3, and 1.0%
concentrations produced a transient but significant reduction of lOP in both the
eyes and SABP for a period of 30 minutes. Similarily unilateral application of
1.0% solution of detomidine produced a transient but significant reduction in
lOP without altering the SABP. Pretreatment with 0.01 % yohimbine solution
produced a blockade of the 1.0% xylazine induced ocular hypotension.
Unilateral application of NG-L-arginine methyl ester (1 .0, 5.0, and 10.0%) to the
left eye has failed to alter both lOP and SABP in dogs. Results of this study
provide additional evidence to support that the alpha-2 adrenoreceptors play an
important role in the maintenance of lOP of the canine eye. Additional
experiments are necessary to characterize the role of nitric oxide in lOP.
Introduction
Alpha-2 adrenergic agonists, such as xylazine and detomidine, have been
used in veterinary medicine as sedatives, muscle relaxants, and analgesics
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(Clark, 1969). Transient hypertension followed by prolonged hypotension,
bradycardia, and heart block are some of the most important side effects of
xylazine (Haskins, 1986; Gross et ai, 1992). It has been demonstrated that
topical administration of alpha-2 adrenergic agonists such as xylazine and
detomidine produced a dose-dependent reduction in intraocular pressure in cats,
rabbits, horses, and goats (Selium, 1990; Kumar, 1976; Hsu, 1985; McClure,
1976; Burke and Potter, 1986). Similarly, there is accumulating evidence to
indicate that many of the alpha-2 adrenoreceptor agonists have been shown to
produce a reduction in intraocular pressure in humans (Hodapp et ai, 1981).
It is interesting to note that apraclonidine (p-amino-clonidine) has been recently
approved for therapy of acute glaucoma following laser surgery in humans.
Nitric oxide is a gaseous tissue soluble intercellular signaling molecule
and an extracellar paracrine factor to carry information between cells
(Nathanson, 1993; Sparrow, 1994). It has recently been evaluated as a
vasodilator and to playa role in the regulation of lOP (Nathanson, 1993; Mandai
et ai, 1994). NO has been studied in the retina of the chick embryo and
endotoxin induced uveitis in rats (Zeevalk, 1994; Mandai et ai, 1994).
Derivatives of L-arginine such as NG-nitro-L-arginine methyl ester have been
extensively used as tools in investigating the role of NO in various physiological
and pathological conditions (Moncada et ai, 1991; Moncada and Higgs, 1993).
Studies concerning the role of alpha-2 adrenergic receptors and/or the
interactions between alpha-2 adrenergic receptors and NO in the maintenance
of lOP in dogs are very limited. The experiments outlined in this thesis are
designed to investigate the effects of alpha-2 adrenergic agonists such as
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xylazine, detomidine and NG-nitro-L-arginine methyl ester, an inhibitor of nitric
oxide, administered unilaterally to the left eye on intraocular pressure and
systemic arterial blood pressure in dogs. In addition, the effects of alpha-2
adrenoreceptor blockade with yohimbine and NO sythase inhibition on xylazine
induced reduction in intraocular pressure as well as systemic arterial blood
pressure were determined.
METHODS AND MATERIALS
Drugs
Xylazi.ne hydrochloride (Rompun®, Haver), detomidine hydrochloride
(Dormosedan®, Orion Corporation, Farmos), proparacaine (Proparacaine®,
Bausch and Lomb), yohimbine hydrochloride (Yobine®, Lloyd Laboratories), NG-
nitro-L-arginine methyl ester hydrochloride (Sigma Laboratories) were purchased
commercially.
Animals
Five adult, healthy, male and female dogs weighing 12.0kg to 35.4kg
were used in this study. Prior to use, the animals were examined for internal
parasites and evidence of systemic and ocular disease. The animals were
housed in indoor single unit kennels and maintained on commercial dog food.
The animals were maintained on 12 hour light and 12 hour dark schedule with
free access to food and water.
Drug Preparation and Dosage
All drugs were prepared in fresh, normal saline daily prior to the
experiments. Xylazine hydrochloride was prepared as 0.1, 0.3, and 1.00/0
solutions. Detomidine hydrochloride was prepared as a 1.00/0 solution.
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Yohimbine hydrochloride was prepared as a 0.01 % solution. NG-nitro-L-arginine
methyl ester was prepared as 1.0, 5.0, and 10.0% solutions.
Experimental Protocol
Five dogs were randomly assigned to different drugs and different
dosages within a given drug. Twenty-four hours were allowed to elapse
between experiments with different doses of a single drug. Seven to ten days
were allowed between experiments with different drugs.
Determination of Intraocular and Systemic Arterial Blood Pressure in Conscious
Dogs
Each animal was individually taken to the examination room and one drop
of proparacaine was applied to both eyes. The dog was placed on an
examination table and a blood pressure cuff with monitor (Critikon-Dinamap tm-
Veterinary Blood Pressure Monitor 8300®) was placed on the distal right
forearm over the radial artery to monitor mean systemic arterial blood pressure
(SABP).
The Mackay Marg Model 12 tonometer (Biotronics) was used to measure
intraocular pressure (lOP). After anesthetizing the eyes with topical application
of proparacanine, the lOP and the mean systemic arterial blood pressure (SABP)
were monitored at 5 minute intervals for 15 minutes. After obtaining basal
recordings of both lOP and SABP, one drop of the individual drugs at the
chosen concentration was placed in the left eye and an equal volume of saline
solution in the right eye. Both the lOP and SABP were monitored at 0, 5, 10,
15, 30, 45, and 60 minutes.
Experiments 1 to 3 were conducted to determine the effects of three different
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doses (0.1, 0.3, and 1.0%) of xylazine hydrochloride on lOP and SABP.
Experiment 4 was conducted to determine the effects of a single dose (1 .0%)
of detomidine on lOP and SABP.
Experiment 5 was conducted to determine the effects of pretreatment (5 to 10
minutes) with yohimbine (0.01 %) on xylazine (0.1 %) effects on lOP and SABP.
Experiment 6 to 8 were conducted to determine the effects of 3 different doses
(1 .0, 5.0, and 10.0%) of NG-nitro-L-arginine methyl ester on lOP and SABP.
Experiment 9 was conducted to determine effects of pretreatment with NG-nitro-
L-arginine methyl ester on xylazine (1.0%) effects on lOP and SABP.
Statistical Analysis
The intraocular pressure and systemic arterial blood pressure are
presented as means + /- standard errors of the mean. These were subjected to
ANOVA by SAS for repeated measures with each dose range and time interval.
When differences were found to be significant, multiple comparisons with 0
time values and between doses were performed using LSD. p < 0.05 was
considered significant.
RESULTS
I. Intraocular and Systemic Arterial Blood Pressure of Conscious Dogs
The intraocular pressures of both left and right eyes varied from 17.8 + /-
0.7 to 22.0 + /- 1.4 mm of Hg in unanesthetised, rested adult, healthy,
conscious dogs of mixed sexes. The systemic arterial blood pressure as
determined by the cuff method in conscious and rested dogs ranged from 76.0
+/- 1.9 to 115.5 +/- 9.0 mmHg.
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II. Effects of Xylazine and Detomidine Hydrochloride on Intraocular Pressure and
Systemic Arterial Blood Pressure
Topical administration of xylazine an.d detomidine to the left eye
produced a significant reduction in intraocular pressure. Xylazine at 0.1%,
0.3%, and 10.0% produced a significant reduction in intraocular pressure
beginning at 5 minutes, reaching a peak of 22.0% at 10 minutes and returning
to the normal values of 0 time. The reduction in lOP doesn't appear to be dose
dependent (Tables 1-3). However, the duration of the effect appears to be
dose dependent with maximum effect lasting to 10 minutes at O. 1% and 30
minutes at 1.0% (Tables 1-3). Similarly,there is a significant reduction in
intraocular pressure of the saline treated right eye following the application of
xylazine at 0.1 , 0.3, and 1.0% solutions to the left eye. Topical administration
of xylazine at 0.1 % to the left eye didn't significantly alter the systemic arterial
blood pressure (Table 1). However, there was a transient reduction in SABP
beginning at 5 minutes returning to control values at 60 minutes with 0.30/0
xylazine solution applied to the left eye (Table 2). Topical administration of
1.0% xylazine hydrochloride solution to the left eye produced a transient
increase in SABP at 5 and 10 minutes followed by a significant decrease in
SABP (Table 3). Topical application of detomidine hydrochloride solution at
1.0% produced a transient but significant reduction in lOP of the left eye from
21.5 + /- 1.5 mmHg at 0 time to 19.0 + /- 1.9, 17.0 + /- 1.3, and 18.0 + /- 2.0
mm of Hg at 0, 15, and 30 minutes respectively (Table 4). There was no
significant change in the lOP of the saline treated right eye (Table 4). There
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TABLE 1: Intraocular pressure (lOP) of the left (aS) and right (00) eyes and
systemic arterial blood pressure (SABP) following topical administration of
xylazine (0.1 %) solution to the left eye of five conscious dogs at various times.
Time (minutes) lOP (mmHg) (Mean ± S.E.) SABP(mmHg)
as 00 Mean ± S.E.
0 17.8 ± 0.7a 18.8 ± 0.5a 88.4 ± 12.4
5 14.4 ± 0.5b 17.0 ± 0.4a 76.4 ± 2.0
10 13.4 ± 0.9b 16.0 ± 0.6b 81.0 ± 2.0
15 17.6±1.2a 19.2 ± 1.0a 87.8 ± 4.5
30 18.4 ± 0.4a 18.8 ± 0.5a 92.2 ± 3.6
. .Means with the same superscripts are not significantly different.
TABLE 2: Intraocular pressure (lOP) of the left (aS) and (00) right eyes and
systemic arterial blood pressure (SABP) following topical administration of
xylazine (0.3%) solution to the left eye of five conscious dogs at various times.
Means with the same superscripts are not significantly different.
Time (minutes) lOP (mmHg) Mean ± S.E. SABP(mmHg)
OS 00 Mean ± S.E.
0 19.4 ± 0.6a 19.4 ± 0.6a 99.4 ± 4.9a
5 15.6 ± 0.7b 16.6 ± 0.9b 78.0 ± 1.4b
10 14.8 ± 0.8c 15.8 ± 0.7b 83.0 ± 1.3b
15 15.0 ± 0.3c 15.6 ± 0.7b 90.2 ± 0.9c
30 14.8 ± 0.6c 16.2 ± 0.2b 89.4 ± 0.9c
45 15.8 ± 0.9b 17.2 ± 0.6b 89.0 ± 1.6c
60 19.2 ± 0.5a 19.2 ± 0.5a 98.5 ± 3.7a
. .
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TABLE 3. Intraocular pressure (lOP) of left (OS) and right (00) eyes and
systemic arterial blood pressure (SABP) following topical administration of
xylazine (1 .00/0) solution to the left eye of five conscious dogs at various times.
Time (minutes) lOP (mmHg) (Mean ± S.E.) SABP (mmHg)
OS 00 Mean ± S.E.
0 19.8 ± 0.8a 19.2 ± 0.7a 76.0 ± 1.9a
5 14.9 ± 0.4b 16.6 ± 0.6b 93.4 ± 3.3b
10 14.2 ± 0.5b 16.2 ± 0.6b 102.9 ± 3.4b
15 14.2 ± 0.6b 17.6 ± 1.0b 86.2 ± 2.1 c
30 15.2 ± 0.5b 17.8 ± 0.9b 74.0 ± 5.4a
45 19.4 ± 1.2a 19.2 ± 0.5a 88.0 ± 1.5c
60 19.6 ± 0.7a 19.6 ± 0.7a 68.0 ± 6.0a
. .Means with the same superscripts are not significantly different.
TABLE 4: Intraocular pressure (lOP) of the left (aS) and right (00) eyes and
systemic arterial blood pressure (SABP) following topical administration of
detomidine (1 .0%) solution to the left eye of four dogs at various times.
Time (minutes) lOP (mmHg) (Mean ± S.E.) SABP (mmHg)
OS 00 Mean ± S.E.
0 21.5 ± 1.5a 20.8 ± 1.0a 115.5 ± 9.0
5 21.0 ± 3.3a 20.5 ± 2.5a 110.5 ± 9.1
10 19.0 ± 1.9c 17.5 ± 2.1 b 93.7 ± 18.3
15 17.0 ± 1.3b 17.7 ± 1.9b 111.5 ± 7.1
30 18.0 ± 2.0b 18.0 ± 2.7b 93.5 ± 5.7
45 20.0 ± 2.9c 19.2 ± 3.3a 108.5 ± 7.3
60 19.5 ± 1.2c 20.0 ± 1.3a 113.5 ± 8.3
..Means with the same superscnpts are not significantly different.
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was no significant change in the SABP when 1.0% detomidine hydrochloride
was applied to the left eye for a period of 60 minutes monitored during the
experiment (Table 4).
III. Effects of Alpha-2 Adrenoreceptor Blockade on lOP and SABP
Pretreatment of the left eye with 0.01 % yohimbine solution for 5-10
minutes appeared to block the reduction in intraocular pressure induced by
topical application of O. 1% xylazine solution to the left eye throughout the 30
minutes of recording period. However, there was no significant alteration in
SABP (Table 5).
IV. Effects of Nitric Oxide Synthase Inhibitors on lOP and SABP
Topical administration of NG-nitro-L-arginine to the left eye at 1.0, 5.0,
and 10.0% solution failed to alter the lOP of both the eyes and systemic arterial
blood pressures of conscious dogs for a period of 1 hour (Tables 6-8).
V. Interactions between the NO Synthase Inhibitor and Xylazine
Pretreatment with NG-nitro-L-arginine methyl ester at 10.00/0 level to the
left eye for 30 minutes failed to alter the reduction in lOP induced by 1.00/0
solution of xylazine hydrochloride at 5 to 30 minutes (Table 9).
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TABLE 5: Intraocular pressure (lOP) of the left (OS) and right (00) eyes and
systemic arterial blood pressure (SABP) following topical administration of
xylazine (0.1 %) solution to the left eye of five conscious dogs pretreated (5-10
min) with 0.01 % yohimbine solution at various times.
Time (minutes) lOP (mmHg) Mean ± S.E.) SABP (mmHg)
OS 00 Mean ± S.E.
0 18.4 ± 0.9 18.6 ± 0.6 78.6 ± 1.4a
5 18.2 ± 0.8 18.8 ± 0.5 82.8 ± 1.2c
10 17.6 ± 0.5 18.6 ± 0.6 65.0 ± 3.7b
15 16.8 ± 0.7 17.8 ± 0.5 97.6 ± 7.4c
20 16.2 ± 0.6 18.4 ± 0.6 92.0 ± 1.1c
25 17.8 ± 0.9 18.0 ± 0.6 88.6 ± 1.9c
30 18.6 ± 0.8 18.6 ± 0.6 98.6 ± 2.3c
..Means with the same superscripts are not significantly different from each
other.
TABLE 6. Intraocular pressure (lOP) of the left (aS) and right (00) eyes and
systemic arterial blood pressure (SABP) following topical administration of NG-
nitro-L-arginine methyl ester solution (1.0%) solution to the left eye of five
conscious dogs at various times.
Time (minutes) lOP (mmHg) (Mean ± S.E.) SABP (mmHg)
as 00 Mean ± S.E.
0 18.8 ± 1.3 18.4 ± 1.3 107.0 ± 5.3
5 19.2 ± 1.2 18.2 ± 1.3 107.0 ± 2.2
10 20.2 ± 1.2 19.2 ± 1.0 116.6 ± 5.9
15 21.2 ± 1.0 19.6 ± 1.5 108.4 ± 2.1
30 20.4 ± 0.9 19.6 ± 0.7 108.6 ± 5.4
45 20.0 ± 1.1 18.0 ± 1.3 113.6 ± 3.8
60 19.6 ± 0.7 18.4 ± 1.2 110.2±2.9
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TABLE 7. Intraocular pressure (lOP) of the left (aS) and right (00) eyes and
systemic arterial blood pressure (SABP) following topical administration of NG-
nitro-L-arginine methyl ester (5.00/0) solution to the left eye of five conscious
dogs at various times.
Time (minutes) lOP (mmHg) (Mean ± S.E.) SABP (mmHg)
as 00 Mean ± S.E.
0 22.0 ± 1.4 22.0 ± 0.9 91.0±7.7
5 22.0 ± 1.8 22.8 ± 1.2 104.8 ± 7.4
10 23.2 ± 1.3 21.6 ± 1.5 114.2 ± 10.6
15 22.4 ± 1.6 22.0 ± 1.1 100.4 ± 3.6
30 21.6 ± 1.2 21.2 ± 1.4 97.6 ± 6.2
45 23.2 ± 1.3 21.8 ± 1.1 94.2 ± 9.1
60 22.0 ± 1.5 21.2 ± 1.0 109.0 ± 9.7
TABLE 8. Intraocular pressure (lOP) of the left (aS) and right (00) eyes and
systemic arterial blood pressure (SABP) following topical administration of NG-
nitro-L-arginine methyl ester (10.0%) solution to the left eye of five conscious
dogs at various times.
Time (minutes) lOP (mmHg) (Mean ± S.E.) SABP (mmHg)
as 00 Mean ± S.E.
0 18.4 ± 1.2 17.2 ± 0.5 103.2 ± 7.3
5 18.4 ± 0.7 18.8 ± 1.5 113.6±9.5
10 17.6±0.7 17.6 ± 0.4 95.0 ± 10.6
15 17.6 ± 0.9 17.6 ± 0.7 108.6 ± 3.0
30 17.0 ± 1.3 17.2 ± 0.8 98.0 ± 10.4
45 18.4 ± 1.6 19.2 ± 0.8 103.0±1.9
60 18.4 ± 1.2 18.8 ± 0.5 103.8 ± 4.9
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TABLE 9. Intraocular pressure (lOP) of the left (OS) and right (00) eyes and
systemic arterial blood pressure (SABP) following topical administration of
xylazine (1 .0%) solution the left eye of five conscious dogs pretreated (30
minutes) with NG-nitro-arginine methyl ester (10.0%) solution at various times.
Time (minutes) lOP (mmHg) (Mean ± S.E.) SABP (mmHg)
OS 00 Mean ± S.E.
0 22.0 ± 1.1 a 20.4 ± 1.3a 117.4 ± 16.9
5 19.6 ± 0.9b 16.8 ± 1.6b 108.8 12.4
10 17.6 ± 0.9c 18.8 ± 1.6b 106.0 ± 5.6
15 17.6 ± 1.9c 17.2 ± 1.3b 101.8 ± 12.2
30 18.0 ± 1.8b 17.6 ± 0.7b 97.4 ± 7.3
45 21.2 ± 1.5a 20.8 ± 0.8a 108.6 ± 4.6
60 21.6 ± 0.9a 20.4 ± 1.2a 104.2 ± 3.7
..Means with the same superscripts are not significantly different from each
other.
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DISCUSSION
The lOP of both left and right eyes and SABP of unanesthesized, rested
adult, healthy, concious dogs of mixed sexes were 17.8 + /- 0.7 to 22.0 + /-
0.9 and 76.0 +/- 1.9 to 115.5 +/- 9.0 mmHg respectively. These values are
consistent with the range of values previously reported (Edwards, 1985; Gelatt,
1991b).
Alpha-2 adrenergic agonists such as xylazine and detomidine appear to
produce a dose dependent transienf but significant reduction in lOP. Xylazine
administered topically produced a significant reduction in lOP at 5 minutes
reaching a peak of 22.0% at 10 minutes. The reduction in lOP doesn't appear
to be dose dependent but the duration appears to be dose dependent with a
maximum duration of 30 minutes with the 1.0% solution (Tables 1-3). There
was a similar reduction of lOP of the saline treated right eye. These results are
similar to those of other studies whereby unilateral topical xylazine
administration lowered lOP bilaterally in unanesthetized rabbits, cats, and
monkeys (Burke, 1986). Detomidine produced a significant but transient
reduction in the lOP of the treated left eye from 21.5 +/-1.5 mmHg at 0 time
to 19.0 + /- 1.9, 17.0 + /- 1.3 and 18.0 + /- 2.0 mmHg at 0, 15, 30 minutes
respectively. There was no significant change in the lOP of the saline treated
right eye. Our results are different from previous reported results in that
detomidine has been reported to produce a significant bilateral decrease in lOP
in rabbits and cats (Jin et ai, 1991). This could be attributed to differences in
species.
The bilateral effects demonstrated by xylazine may be explained by two
possible mechanisms: a eNS mediated effect and/or systemic transfer of the
drug to the opposite eye that may be dose dependent (Burke, 1986). Other
studies supporting the systemic transfer, dose dependent mechanism also have
shown a unilateral miosis and a suppressive effect in the cat nictitating
membrane of arterially administered xylazine (Burke, 1986).
Topical application of xylazine to the left eye produced a transient
reduction in SABP at 5 minutes with 0.3% solution. With the 1.0% xylazine
solution, there was a transient hypertension at 5 and 10 minutes followed by
a significant hypotension. This is consistent with other reported studies of
xylazine (Gross et ai, 1992; Antonaccio, 1973). There are currently no reports
on the 'pharmacokinetics of xylazine following its topical applicatioin to the
eyes. It is possible that the systemic effects of xylazine on cardiovascular
system following ocular application is mediated via some of the xylazine being
carried from the site of application to the systemic circulation. It would be of
great interest to characterize both the pharmacodynamic and pharmacokinetic
profiles of drugs applied topically to the eyes. There was no significant change
in SABP with topical 1.0% detomidine administration. This is in contrast to the
decreased heart rate with hypertension then a gradual return to normal reported
in mature and yearling horses (England, 1992). This may be explained by the
possible route and amount of administraion -- topical versus intravenous or
intramuscular. There is accumulating evidence to indicate the presence of a
large number of alpha-2 adrenergic receptors in various ocular structures
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particularly blood vessels (Mittag, 1985). The large number of alpha-2
adrenergic receptors present in the intraocular vascular bed have been
demonstrated to regulate the vascular tone. A reduction in aqueous formation
and/or increase in outflow have been observed when the vascular tone is
reduced via activation of presynaptic alpha-2 adrenoreceptors with selective
alpha-2 adrenergic agonists. Vasodilation of vessels in the ciliary processes
could lower the ultrafiltration rate which could account for a decrease in
aqueous humor formation (Innemee et ai, 1981; Innemee and Van Zwieten,
1979; Langham, 1982; Lorenzetti, 1971).
Results of the present study provide additional support that the
intraocular alpha-2 adrenergic receptors play an important role in modulating the
intraocular pressure in the canine eye. It has been previously demonstrated that
the reduction of intraocular pressure with adrenergic agents could possibly be
mediated via an increase in cyclic AMP in the aqueous humor (Newfeld et ai,
1972).
It has been further shown that the ocular hypotensive effect of
medetomidine in rabbits and cats could be mediated via inhibition of adenylate
cyclase in the ciliary processes (Jin et ai, 1991).
Yohimbine is a selective alpha-2 adrenergic antagonist (Hsu, 1993). The
bilateral decrease in lOP exhibited with topical unilateral administration of
xylazine was eliminated when the treated eye was pretreated with yohimbine.
Yohimbine antagonizes or blocks the alpha-2 agonist xylazine. This allows
norepinephrine release which stimulates the post junctional alpha-1 receptors
which in turn stimulates the ciliary body epithelium to continue aqueous humor
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production and maintain a constant intraocular pressure.
A substantial body of basic research has established the importance of
NO (EDRF-endothelium derived relaxing factor) in both basal and stimulated
control of vascular tone. It has been demonstrated that the basal level of cyclic
GMP are higher in vascular strips when the endothelium is intact than when it
has been removed. It has been further shown that there is a basal release of
NO from various blood vessels. A large number of studies have used L-arginine
derivatives as inhibitors of NO synthase and demonstrated that the NO is the
key mediator of vasodilation (Anderson et ai, 1994). Nitrovasodilators such as
nitroglycerine, amylnitrite, sodium nitroprusside, and hydralazine have been
shown to produce either a increase or decrease in lOP in rabbits and monkeys
respectively (Nathanson, 1993). Recent studies have demonstrated the
existence of a NO-cGMP system in the segment of the eye (Nathanson, 1993).
However, studies concerning the role of NO in the maintenance of lOP are at
present nonexistent. Our results, although preliminary in scope, with the
topical application of NG-nitro-L-arginine methyl ester, an inhibitor of
endogenous NO, failed to produce an alteration either in lOP or SABP. The
failure of NO synthase inhibitor to produce any change in lOP and SABP could
possibly be due to inability of the drug to reach the site of action or the thirty
minute period following the application of the drug might not be sufficient time
to inhibit the NO-cGMP system within the eye. Therefore, further studies are
necessary before one could rule out the possib"le role of NO in the maintenance
of lOP in the canine eye.
In conclusion, the results presented in this study provide evidence that
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topical administration of alpha-2 adrenoreceptor agonists such as xylazine and
detomidine produce a transient but significant reduction of lOP in the dog.
Blockade of xylazine induced reduction in lOP with yohimbine indicates that
alpha-2 adrenoreceptors in the eye playa role in the control of lOP. Further
studies are necessary to characterize the role of NO in the maintenence of
intraocular pressure.
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CONCLUSIONS AND SUMMARY
Administration of a-2 adrenoreceptor agonists including xylazine and
detomidine topically to the cornea caused a decrease in intraocular pressure in
both eyes. The decrease in the contralateral eye's intraocular pressure was not
as dramatic or as prolonged as the treated eye. With an increase in the
concentration of xylazine, the lOP remained depressed for longer periods of
time.
The decrease in intraocular pressure was eliminated when the selective
alpha-2 antagonist yohimbine was administered prior to xylazine application.
The effect of both xylazine and detomidine on intraocular pressure can
be explained by the fact that prejunctional alpha-2 agonists have autoinhibitory
effects on norepinephrine release. This, in turn, causes a decrease in aqueous
humor production and therefore lowered intraocular pressure. The use of
yohimbine further explains these results. Yohimbine antagonizes or blocks the
alpha-2 agonist xylazine. This allows norepinephrine release which stimulates
the post junctional alpha-1 receptors which then stimulate the ciliary body
epithelium to continue aqueous humor production and maintain a constant
intraocular pressure.
The decrease in the pressure of the contralateral eye can be explained by
the systemic transfer of drug that is also dose-dependent.
A large number of studies have used L-arginine derivatives such as NG-L-
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arginine as inhibitors of NO synthase and demonstrates that the NO is the key
mediator of vasodilation. Topical application of NG-nitro-L-arginine methyl ester
to the left eye with an up to 10.0% solution failed to produce a significant
alteration either in lOP or SABP in conscious dogs. Based on the results
presented in this thesis, one could conclude that the 0- 2 receptors are more
susceptible to the effects of the alpha-2 agonists and additional experiments are
necessary to support the role of NO in the maintenance of intraocular in the
canine eye.
Although these were clinically normal dogs, it may be relevant to
consider the use of an alpha-2 agonist in combination with the typical beta
blockers or carbonic anhydrase inhibitors that are currently in use for glaucoma
or increased intraocular pressure therapy.
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